292606-35-0

Usage

Uses

Used in Chemical Synthesis:
1-BOC-AMINO-2,2-DIMETHYL-1,3-PROPANEDIAMINE is used as a reagent in chemical synthesis for its ability to participate in various chemical reactions due to its trivalent N-BOC protected diamine functional group.
Used in Pharmaceutical Research:
1-BOC-AMINO-2,2-DIMETHYL-1,3-PROPANEDIAMINE is used as a research compound in pharmaceutical research for its potential applications in drug discovery and development.
Used in Polymer and Resin Production:
1-BOC-AMINO-2,2-DIMETHYL-1,3-PROPANEDIAMINE is used as a building block in the creation of various synthetic products, such as polymers and resins, due to its chemical properties and reactivity.
Used in Drug Discovery and Development:
1-BOC-AMINO-2,2-DIMETHYL-1,3-PROPANEDIAMINE is used as a component in drug discovery and development, where its unique structure and reactivity can contribute to the design and synthesis of new pharmaceutical compounds.

InChI:InChI=1/C10H22N2O2/c1-9(2,3)14-8(13)12-7-10(4,5)6-11/h6-7,11H2,1-5H3,(H,12,13)

Upstream product

• 7328-91-8 2,2-Dimethyl-1,3-diaminopropane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1384724-40-6 C₁₂H₂₁F₃N₂O₃ 
• 1321622-57-4 N-(3-amino-2,2-dimethylpropyl)-2,2,2-trifluoroacetamide 

Downstream Products

• 1384724-42-8 tert-butyl (2,2-dimethyl-3-(2-nitrophenylsulfonamido)propyl)carbamate 
• 1604813-29-7 tert-butyl (3-(4-((4-((4-(3-bromopropoxy)-3-chlorobenzyl)amino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl)amino)benzamido)-2,2-dimethylpropyl)carbamate 
• 1604812-99-8 C₃₆H₃₆F₃N₉O₅ 
• 1604812-98-7 C₃₅H₃₅ClF₄N₈O₅ 
• 1604813-22-0 tert-butyl 3-(4-(4-(4-(2-(chloromethyl)allyloxy)benzylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-ylamino)benzamido)-2,2-dimethylpropylcarbamate 
• 1449410-37-0 tert-butyl 3-(4-{[4-(1-(4-chlorophenyl)cyclopropylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]amino}benzamido)-2,2-dimethylpropylcarbamate 
• 1430195-72-4 tert-butyl (3-(4-((4-((4-(3-bromopropoxy)benzyl)amino)-6-(2,2,2-trifluoroethoxy)pyrimidin-2-yl)amino)benzamido)-2,2-dimethylpropyl)carbamate 

Relevant academic research and scientific papers

3-OXO-1,4-DIAZEPINYLE COMPOUNDS AS NRF2 ACTIVATORS

The present invention relates to bisaryl lactam compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the compounds of this invention include a compound of Formula (I):

Csp3-H bond activation with triel metals: Indium and gallium zwitterions through internal hydride abstraction in rigid salan ligands

The hydropyrimidine salan (salan=N,N'-dimethyl-N,N'-bis[(2-hydroxyphenyl) methylene]-1,2-diaminoethane) proteo-ligands with a rigid backbone {ON^(CH 2)^NO}H2 react with M(CH2SiMe3) 3 (M=Ga, In) to yie

Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug

The embodiments provide Compound KC-8, N-1-[3-(oxycodone-6-enol-carbonyl-methyl-amino)-2,2-dimethyl-propylamine]-arginine-glycine-malonic acid, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the compositions comprise a prodrug, Compound KC-8, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

5-Substituted isoquinoline derivatives

A compound represented by the following formula (1) or a salt thereof: wherein R1 represents hydrogen atom, a halogen atom and the like; R2 represents hydrogen atom, a halogen atom, a C1-6 alkyl group and the like; and R3 represents —O—X—C(A1)(A11)—C(A2)(A2l)—N(A3l)(A3)(X represents propylene group etc., A11 and A21 represent hydrogen atom, or a C1-6 alkyl group, A31 represents a C1-6 alkyl group substituted with hydroxyl group, or hydrogen atom, and A1, A2, and A3 represent hydrogen atom, a C1-6 alkyl group and the like) and the like, which has an inhibitory activity on the phosphorylation of myosin regulatory light chain, and is useful for treatment of diseases relating to contraction of various cells and the like.

AMINE COMPOUNDS AND USE THEREOF

It is intended to provide novel amine compounds which are efficacious against diseases such as infection with HIV virus, rheumatism and cancer metastasis. Namely, amine compounds represented by the following general formula (1):In a typical case, A1 and A2 represent each an optionally substituted monocyclic or polycyclic aromatic heterocycle; W represents cyclic C3-10 alkylene, an optionally substituted monocyclic or polycyclic aromatic heterocycle, a monocyclic or polycyclic aromatic ring or a partly saturated polycyclic aromatic ring; X represents O, CH2, C(=O) or NR11; and D is a group represented by the following general formula (4) or (6).-Q-Y-BIn the formula (6), Q represents a single bond, S, O or NR12; and Y is a group represented by the following general formula (7). z represents an optionally substituted monocyclic or polycyclic aromatic ring. In the formula (6), B represents NR25R26. In the above formulae, R1 to R26 each represents hydrogen, alkyl, alkenyl or alkynyl.

Solution parallel synthesis of cyclic guanidines

An efficient method for the solution phase synthesis of cyclic guanidines is presented. A variety of 2-substituted monoprotected propanediamines react with a set of 5-substituted 2-methylthio-3,4,5,6- tetrahydropyrimidines under Rathke conditions for the construction of a potential library of 81 cyclic guanidines.

Design and synthesis of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)- en-2-yl)-ethyl]phosphonic acid (EAA-090), a potent N-methyl-D-asparate antagonist, via the use of 3-cyclobutene-1,2-dione as an achiral α-amino acid bioisostere

The diazabicyclic amino acid phosphonate 15, [2-(8,9-dioxo-2,6- diazabicyclo[5.2.0]non-1(7)-en-2-yl)ethyl]phosponic acid, was identified as a potent NMDA antagonist. It contains the α-amino acid bioisostere 3,4- diamino-3-cyclobutene-1,2-dione and an addi